Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021

Ascierto, Paolo A.; Avallone, Antonio; Bhardwaj, Nina; Bracarda, Sergio; Brody, Joshua; Buonaguro, Luigi; Demaria, Sandra; Emens, Leisha A.; Ferris, Robert L.; Galon, Jérôme; Khleif, Samir N.; Klebanoff, Christopher A.; Laskowski, Tamara; Melero, Ignacio; Paulos, Chrystal M.; Pignata, Sandro; Ruella, Marco; Svane, Inge Marie; Taube, Janis M.; Fox, Bernard A.; Hwu, Patrick; Puzanov, Igor

doi:10.1186/s12967-022-03471-y

Cited by 5 publications

(4 citation statements)

References 104 publications

(101 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, antigen loss has been the most frequently studied mechanism of relapse or resistance in CAR-T cells after treatment ( 27 , 96 – 99 ).…”

Section: Car-t Treatment Resistance/recurrence Mechanismmentioning

confidence: 99%

Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas

Wang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Genetically modified T-cell immunotherapies are revolutionizing the therapeutic options for hematological malignancies, especially those of B-cell origin. Impressive efficacies of CD19-directed chimeric antigen receptor (CAR)-T therapy have been reported in refractory/relapsed (R/R) B-cell non-Hodgkin lymphoma (NHL) patients who were resistant to current standard therapies, with a complete remission (CR) rate of approximately 50%. At the same time, problems of resistance and relapse following CAR-T therapy have drawn growing attention. Recently, great efforts have been made to determine various factors that are connected to the responses and outcomes following CAR-T therapy, which may not only allow us to recognize those with a higher likelihood of responding and who could benefit most from the therapy but also identify those with a high risk of resistance and relapse and to whom further appropriate treatment should be administered following CAR-T therapy. Thus, we concentrate on the biomarkers that can predict responses and outcomes after CD19-directed CAR-T immunotherapy. Furthermore, the mechanisms that may lead to treatment failure are also discussed in this review.

show abstract

“…To date, antigen loss has been the most frequently studied mechanism of relapse or resistance in CAR-T cells after treatment ( 27 , 96 – 99 ).…”

Section: Car-t Treatment Resistance/recurrence Mechanismmentioning

confidence: 99%

Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas

Wang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Despite its potential to enhance survival rates and provide a long-lasting curative impact on cure, immunotherapy is only suitable for certain individuals and often has a low response rate (Ascierto et al, 2022). Thereby, combination therapy is necessary for patients with weakened immunity or cancer forms that are less responsive to immunotherapy.…”

Section: Immunotherapymentioning

confidence: 99%

Living virus‐based nanohybrids for biomedical applications

Jin,

Mao

2023

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Living viruses characterized by distinctive biological functions including specific targeting, gene invasion, immune modulation, and so forth have been receiving intensive attention from researchers worldwide owing to their promising potential for producing numerous theranostic modalities against diverse pathological conditions. Nevertheless, concerns during applications, such as rapid immune clearance, altering immune activation modes, insufficient gene transduction efficiency, and so forth, highlight the crucial issues of excessive therapeutic doses and the associated biosafety risks. To address these concerns, synthetic nanomaterials featuring unique physical/chemical properties are frequently exploited as efficient drug delivery vehicles or treatments in biomedical domains. By constant endeavor, researchers nowadays can create adaptable living virus‐based nanohybrids (LVN) that not only overcome the limitations of virotherapy, but also combine the benefits of natural substances and nanotechnology to produce novel and promising therapeutic and diagnostic agents. In this review, we discuss the fundamental physiochemical properties of the viruses, and briefly outline the basic construction methodologies of LVN. We then emphasize their distinct diagnostic and therapeutic performances for various diseases. Furthermore, we survey the foreseeable challenges and future perspectives in this interdisciplinary area to offer insights.This article is categorized under: Biology‐Inspired Nanomaterials > Protein and Virus‐Based Structures Therapeutic Approaches and Drug Discovery > Emerging Technologies

show abstract

“…However, for some patients with advanced-stage or special pathological types such as Triple-negative breast cancer (TNBC) and c-erbB-2 positive breast cancer, the current treatment cannot prevent the progression of the disease effectively [3]. Immunotherapy has made a great breakthrough in the treatment of advanced solid tumors by regulating the body's anti-tumor immune response and enhancing immune function to identify and eliminate tumor cells, which also provides new insights into the comprehensive treatment of Ivyspring International Publisher advanced breast cancer [4,5,6,7,8,9,10].…”

Section: Introductionmentioning

confidence: 99%

PD-1/PD-L1 Inhibitor - Related Adverse Events and Their Management in Breast Cancer

Lei,

Kong,

et al. 2024

J. Cancer

View full text Add to dashboard Cite

As the positive results of multiple clinical trials were released, the Programmed cell death 1 (PD-1) and Programmed cell death ligand 1 (PD-L1) inhibitors emerge as the focus of integrative breast cancer treatment. PD-1/PD-L1 inhibitors are often used as a sequential agent to be combined with other agents such as chemotherapeutic agents, targeted agents, and radiation therapy. As multiple therapies are administered simultaneously or in sequence, they are prone to a variety of adverse effects on patients while achieving efficacy. It is a challenge for clinicians to maintaining the balance between immune-related adverse effects(irAEs) and treatment efficacy. Previous literatures have paid lots of attention on the adverse effects caused by immunosuppressive agents themselves, while there is a dearth of the research on the management of adverse immune effects during the combination of immunotherapy with other treatments. In this review, we discuss the overall incidence of irAEs caused by PD-1/PD-L1 inhibitors in combination with various types of treatments in breast cancer, including chemotherapy, CTLA-4 inhibitors, targeted therapy, and radiotherapy, and systematically summarizes the clinical management to each organ-related adverse immune reaction. It is important to emphasize that in the event of irAEs such as neurological, hematologic, and cardiac toxicity, there is no alternative treatment but to terminate immunotherapy. Thus, seeking more effective strategy of irAEs' management is imminent and clinicians are urged to raise the awareness of the management of adverse immune reactions.

show abstract

Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021

Cited by 5 publications

References 104 publications

Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas

Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas

Living virus‐based nanohybrids for biomedical applications

PD-1/PD-L1 Inhibitor - Related Adverse Events and Their Management in Breast Cancer

Contact Info

Product

Resources

About